# Cardiovascular Effects of GLP-1 Receptor Activation

> **NCT03101930** · PHASE4 · COMPLETED · sponsor: **Vanderbilt University Medical Center** · enrollment: 329 (actual)

## Conditions studied

- Obesity
- PreDiabetes

## Interventions

- **DRUG:** Liraglutide
- **DRUG:** Sitagliptin
- **OTHER:** hypocaloric diet
- **DRUG:** Placebos
- **DRUG:** Exendin (9-39)

## Key facts

- **NCT ID:** NCT03101930
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-01
- **Primary completion:** 2021-06-24
- **Final completion:** 2021-06-24
- **Target enrollment:** 329 (ACTUAL)
- **Last updated:** 2022-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03101930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03101930, "Cardiovascular Effects of GLP-1 Receptor Activation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03101930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*